Improvement of adherence to guidelines for antiemetic medication enhances emetic control in patients with colorectal cancer receiving chemotherapy of moderate emetic risk

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5549-5556

  Fujii, Hironori ^a   Iihara, Hirotoshi ^a   Ishihara, Masashi ^a   Takahashi, Takao ^b   Yoshida, Kazuhiro ^b   Itoh, Yoshinori ^a  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adherence; Chemotherapy induced nausea and vomiting; Colorectal cancer; Dexamethasone; Moderately emetic chemotherapy

Indexed keywords

ANTIEMETIC AGENT; DEXAMETHASONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; VERY ELDERLY;

EID: 84891402213     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M and Herrstedt J: Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24: 4472-4478, 2006.
2. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, Beurden V, Stoter G and Verweij J: Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. Br J Cancer 76: 1055-1061, 1997.
3. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A and Khayat D: Changing patient perceptions of the side-effects of cancer chemotherapy. Cancer 95: 155-163, 2002.
4. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN and Lyman GH: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-4198, 2011.
5. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M and Warr D: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Annal Oncol 21(suppl 5): v232-243, 2010.
6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Antiemesis. Version I, 2013. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/antiemesis.pdf.
7. Burmeister H, Aebi S, Studer C, Fey MF and Gautschi O: Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20: 141-147, 2012.
8. Gomez DR, Liao KP, Giordano S, Nguyen H, Smith BD and Elting LS: Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: A population-based study. Cancer 119: 1428-1436, 2013.
9. Chan A, Low XH and Yap KY: Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm 18: 385-394, 2012.
10. Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez- Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P and Roila F: The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23: 1986-1992, 2012.
11. Koch S, Wein A, Siebler J, Boxberger F, Neurath MF, Harich HD, Hohenberger W and Dörje F: Antiemetic prophylaxis and frequency of chemotherapyinduced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: The Northern Bavarian IVOPAK I Project. Support Care Cancer 2013 (DOI 10.1007/s00520-013-1801-z).
12. Guyatt GH: Evidence-based medicine. ACP J Club 114(suppl 2): A-16, 1991.
13. Evidence-Based Medicine Working Group: Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 268: 2420-2425, 1992.
14. Buchan H. Gaps between best evidence and practice: Causes for concern. Med J Aust 180(6 suppl): 48-49, 2004.
15. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A and Kerr EA: The quality of health care delivered to adults in the United States. New Engl J Med 348: 2635-2645, 2003.
16. Fraunholz I, Grau K, Weiss C and Rödel C: Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol 187: 1-6, 2011.
17. Sekine I, Segawa Y, Kubota K and Saeki T: Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis. Cancer Sci 104: 711-717, 2013.
18. Hesketh PJ, Aapro M, Street JC and Carides AD: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18: 1171-1177, 2010.
19. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM and Aaronson NK: Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study. Support Care Cancer 20: 107-117, 2012.
20. Hesketh PJ, Sanz-Altamira P, Bushey J and Hesketh AM: Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 20: 1043-1047, 2012.
21. Roscoe JA, Heckler CE, Morrow GR, Mohile SG, Dakhil SR, Wade JL and Kuebler JP: Prevention of delayed nausea: A University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 30: 3389-3395, 2012.
22. Roila F, Warr D, Aapro M, Clark-Snow RA, Einhorn L, Gralla RJ, Herrstedt J, Saito M and Tonato M: Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer 19(suppl 1): S57-62, 2011.
23. Vardy J, Pond G, Dodd A, Warr D, Seruga B, Clemons M, Bordeleau L, Goodwin P and Tannock IF: A randomized doubleblind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 136: 143-151, 2012.